| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 05 Aug 2026 |
8-K: Regulation FD Disclosure
August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Co... |
| 26 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Context Therapeutics Inc. (the “Company”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corp... |
| 01 May 2026 |
8-K: Other Events
As previously disclosed, on March 11, 2026, the Court of Chancery of the State of Delaware (the “Court”) approved a stipulation and proposed consent judgment (the “Stipulated Judgment”) regarding the stockholder class action complaint (t... |
| 02 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer |
| 23 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 13 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
CERTIFICATE OF CORRECTIONOFAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOFCONTEXT THERAPEUTICS INC. |
| 27 Feb 2026 |
8-K: Other Events
On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court of Chancery of the State of Delaware (the “Court”) regarding the stockholder class action complaint (the “Action”) fil... |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
January 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 05 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
November 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 24 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Amendment No. 1 (this “Amendment”) to the Sales Agreement, dated December 2, 2024 (the “Original Agreement”) is entered into as of the date first written above by Context Therapeutics Inc. (the “Company”) and Leerink Partners LLC (t... |
| 20 Oct 2025 |
8-K: Other Events
As previously disclosed by Context Therapeutics Inc. (the “Company”) on that certain Current Report on Form 8-K filed on February 28, 2025 with the U.S. Securities and Exchange Commission (the “SEC”), on February 27, 2025, the Company re... |
| 02 Sep 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar d... |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Context Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2025, the record date for the Annual Meeting, there were 89,704,194 shares of common stock i... |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors |
| 09 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody |
| 28 Feb 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On February 27, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(... |
Loading...